Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Ultra Drugs Pvt Ltd

    Ultra Drugs Pvt Ltd was incorporated as a private limited company in 2006 with Mr Sangram Singh as its Managing Director and Dr Minna Jakhar and Mr Malwinderjeet Singh as its di

  • No Image
    Umbilical Pharmaceuticals Pvt Ltd

    Umbilical Pharmaceuticals Private Limited (UPPL) is an enterprise in the field of manufacturing generic medicines. Its commercial operations of the company started in January 2

  • No Image
    Unichem Laboratories Ltd

    Promoted by a pioneer of the Indian pharmaceuticals business, Mr. Amrut Mody, Unichem Laboratories has grown to become one of India?s most respected pharmaceutical companies. By